Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Poland
Poland- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
15 trials match your criteria
Recruiting
Primary progressive multiple sclerosis
RecruitingInvestigational
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:–
Countries:Poland
Poland- Participants:18–64 years
Recruiting
Migraine
RecruitingRegistered drug
Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks
Registered drug
- Disease:Migraine
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Recruiting
Migraine
RecruitingRegistered drug
Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients
Registered drug
- Disease:Migraine
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Recruiting
Relapsing multiple sclerosis
RecruitingRegistered drug
Study on the Effectiveness of Ublituximab and Drug Combination for Patients with Relapsing Multiple Sclerosis
Registered drug
- Disease:Relapsing multiple sclerosis
- Substances:CetirizineDexamethasone+5
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Cetirizine
Recruiting
Secondary progressive multiple sclerosis
RecruitingInvestigational
A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Investigational
- Disease:Secondary progressive multiple sclerosis
- Substances:Remibrutinib
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Remibrutinib
Recruiting
Multiple sclerosis
RecruitingRegistered drug
A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis
Registered drug
- Disease:Multiple sclerosis
- Substances:OcrelizumabRO7268489
Countries:Poland
Poland- Participants:18–64 years
- Substances:Ocrelizumab
Recruiting
Prostate cancer metastatic
RecruitingRegistered drug
Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer
Registered drug
- Disease:Prostate cancer metastatic
- Substances:Abiraterone AcetateDarolutamide+2
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Abiraterone Acetate
Not recruiting
Multiple sclerosis
Not recruitingRegistered drugNo placebo
Study Comparing CT-P53 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis
Registered drugNo placebo
- Disease:Multiple sclerosis
- Substances:MethylprednisoloneOcrelizumab+2
Countries:Poland
Poland- Participants:18–64 years
- Substances:Methylprednisolone
Not recruiting
Dementia Alzheimer's type
Not recruitingRegistered drug
Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease
Registered drug
- Disease:Dementia Alzheimer's type
- Substances:Florbetaben (18F)Florbetapir (18F)+3
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Florbetaben (18F)
Not recruiting
Multiple sclerosis
Not recruitingRegistered drugNo placebo
A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis
Registered drugNo placebo
- Disease:Multiple sclerosis
- Substances:Ocrelizumab
Countries:Poland
Poland- Participants:18–64 years
- Substances:Ocrelizumab
Not recruiting
Multiple sclerosis
Not recruitingRegistered drug
Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis
Registered drug
- Disease:Multiple sclerosis
- Substances:–
Countries:Poland
Poland- Participants:18–64 years